,45,46,47 Indeed, our findings provide strong support for the decision to exclude patients with grade 3, comedonecrosis, or a HER2+ subtype DCIS from active surveillance in these trials. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.